Treatment of visceral leishmaniasis in 2010: direction from Bihar State, India.
Murray
Henry W
HW
D000666:Amphotericin B / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use; D000818:Animals; D000981:Antiprotozoal Agents / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use*; D004359:Drug Therapy, Combination / Q000191:economics; D006801:Humans; D007194:India; D007893:Leishmania donovani / Q000187:drug effects*; D007898:Leishmaniasis, Visceral / Q000188:drug therapy* / Q000469:parasitology; D010303:Paromomycin / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use; D010767:Phosphorylcholine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000191:economics / Q000627:therapeutic use; D016896:Treatment Outcome
D000981:Antiprotozoal Agents; C068538:liposomal amphotericin B; D010767:Phosphorylcholine; C039128:miltefosine; D010303:Paromomycin; D000666:Amphotericin B